.

Marinus Pharmaceuticals reported $23.11M in Current Liabilities for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US $ 117.68M 1.92M
ALKERMES ALKS:US $ 438.52M 23.84M
Amgen AMGN:US $ 12618M 268M
Aptinyx Inc APTX:US $ 5.68M 945K
Biogen BIIB:US $ 5018M 1071.4M
Eisai 4523:JP Y 301894M 11439M
Enanta Pharmaceuticals ENTA:US $ 23.04M 7.7M
Esperion Therapeutics ESPR:US $ 82.28M 3.19M
Gilead Sciences GILD:US $ 9220M 662M
Intercept Pharmaceuticals ICPT:US $ 151.43M 0.39M
Intra Cellular Therapies ITCI:US $ 70.63M 11.56M
Marinus Pharmaceuticals MRNS:US $ 23.11M 3.57M
Minerva Neurosciences NERV:US $ 3.41M 0.16M
Neurocrine Biosciences NBIX:US $ 285.7M 32.2M
Ptc Therapeutics PTCT:US $ 567.37M 90.6M
Regeneron Pharmaceuticals REGN:US $ 3033.9M 26.3M
Sarepta Therapeutics SRPT:US $ 545.57M 90.6M
Supernus Pharmaceuticals SUPN:US $ 735.54M 450.98M
Vertex Pharmaceuticals VRTX:US $ 2556.2M 376M
YTE INCY:US $ 926.67M 40.51M